Abughosh Susan M, Wang Xin, Serna Omar, Henges Chris, Masilamani Santhi, Essien Ekere James, Chung Nancy, Fleming Marc
1 Assistant Professor, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, Texas.
2 Graduate Student, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, Texas.
J Manag Care Spec Pharm. 2016 Jan;22(1):63-73. doi: 10.18553/jmcp.2016.22.1.63.
Patients with comorbid hypertension (HTN) and diabetes mellitus (DM) are at a high risk of developing macrovascular and microvascular complications of DM. Controlling high blood pressure can greatly reduce these complications. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are recommended for patients with both DM and HTN by the American Diabetes Association guidelines, and their benefit and efficacy in reducing macrovascular and microvascular complications of DM have been well documented. Poor adherence, however, remains a significant barrier to achieving full effectiveness and optimal outcomes.
To examine the effect of a brief pharmacist telephone intervention in identifying adherence barriers and improving adherence to ACEI/ARB medications among nonadherent patients with comorbid HTN and DM who are enrolled in a Medicare Advantage plan.
Cigna-HealthSpring's medical claims data was used to identify patients with HTN and DM diagnoses by using ICD-9-CM codes 401 and 250, and at least 2 fills for ACEIs or ARBs between January 2013 and October 2013. Patients who failed to refill their medication for more than 1 day and had a proportion of days covered (PDC) < 0.8 were considered nonadherent and were contacted by a pharmacist by phone to identify adherence barriers. Two outcome variables were evaluated: The first was adherence to ACEIs/ARBs, defined as PDC during the 6 months following the phone call intervention. The second outcome variable was a categorical outcome of discontinuation versus continuation. Discontinuation was defined as not using ACEIs/ARBs during the 6-month post-intervention period. Patients who disenrolled from the plan in 2014 or were switched to another medication commonly used for treating DM and HTN were excluded from further analysis. Descriptive statistics were conducted to assess the frequency distribution of sample demographic characteristics at baseline. Multiple linear regression was conducted to assess the intervention effect on adherence during the 6 months post-intervention using the first outcome of post-intervention PDC, adjusting for baseline PDC and other covariates. Logistic regression was performed to assess the association between medication discontinuation and other baseline characteristics using the second outcome of discontinuation. Other control variables in the models included demographics (age, sex, language), physician specialty (primary care vs. specialist), health plan (low-income subsidy vs. other), Centers for Medicare & Medicaid risk score, Charlson Comorbidity Index, and number of distinct medications.
In total, 186 hypertensive diabetic patients, nonadherent to ACEIs/ARBs (PDC < 0.8), were included in the study. Of the 186 patients, 87 received the pharmacist phone call intervention. Among these patients, forgetfulness (25.29%) and doctor issues, such as having difficulty scheduling appointments (16.79%), were the most commonly reported barriers. After excluding those who switched from ACEIs/ARBs to another medication, 157 patients were included in the logistic regression model. Of those, 131 had continued using ACEIs/ARBs and were included in the linear regression model. The mean (±SD) post-intervention PDC for the intervention group was 0.58 (±0.26) and for the control group 0.29 (±0.17). Intervention was a significant predictor of better adherence in the linear regression model after adjusting all the other baseline covariates (β = 0.3182, 95% CI = 0.19-0.38, P < 0.001). Other covariates were not significantly associated with better adherence. In the logistic regression model (discontinuation: 26 [yes]/131 [no]) for predicting medication discontinuation, patients who received intervention were more likely to continue using ACEIs/ARBs (OR = 3.56, 95% CI = 1.06-11.86), and those with a higher comorbidity index were less likely to continue using them (OR = 0.72, 95% CI = 0.53-0.99).
The brief pharmacist telephone intervention resulted in significantly better PDCs during the 6 months following the intervention as well as lower discontinuation rates among a group of nonadherent patients with comorbid HTN and DM. The overall PDC rates in both the intervention and control groups were still lower than the recommended 80%. Improving adherence to clinically meaningful values may require more than a brief pharmacist phone call. Incorporating motivational interviewing techniques with follow-up calls to address adherence barriers may be more influential in forming sustainable behavioral change and enhancing medication adherence.
合并高血压(HTN)和糖尿病(DM)的患者发生糖尿病大血管和微血管并发症的风险很高。控制高血压可大大降低这些并发症的发生。美国糖尿病协会指南推荐血管紧张素转换酶抑制剂(ACEI)或血管紧张素II受体阻滞剂(ARB)用于同时患有糖尿病和高血压的患者,它们在降低糖尿病大血管和微血管并发症方面的益处和疗效已有充分记录。然而,依从性差仍然是实现完全有效性和最佳结果的重大障碍。
研究药师简短电话干预对识别参加医疗保险优势计划的合并高血压和糖尿病的非依从性患者的依从性障碍及提高其对ACEI/ARB药物依从性的效果。
使用信诺健康春天公司的医疗理赔数据,通过国际疾病分类第九版临床修订本(ICD-9-CM)编码401和250识别患有高血压和糖尿病的患者,并在2013年1月至2013年10月期间至少有2次ACEI或ARB的配药记录。未能重新配药超过1天且覆盖天数比例(PDC)<0.8的患者被视为非依从性患者,药师通过电话联系他们以识别依从性障碍。评估了两个结果变量:第一个是对ACEI/ARB的依从性,定义为电话干预后6个月内的PDC。第二个结果变量是停药与继续用药的分类结果。停药定义为干预后6个月内未使用ACEI/ARB。2014年退出该计划或改用另一种常用于治疗糖尿病和高血压的药物的患者被排除在进一步分析之外。进行描述性统计以评估基线时样本人口统计学特征的频率分布。使用干预后PDC的第一个结果进行多元线性回归,以评估干预对干预后6个月依从性的影响,并对基线PDC和其他协变量进行调整。进行逻辑回归以使用停药的第二个结果评估药物停药与其他基线特征之间的关联。模型中的其他控制变量包括人口统计学特征(年龄、性别、语言)、医生专业(初级保健与专科)、健康计划(低收入补贴与其他)、医疗保险和医疗补助服务中心风险评分、查尔森合并症指数以及不同药物的数量。
共有186例高血压糖尿病患者,对ACEI/ARB不依从(PDC<0.8),纳入本研究。在这186例患者中,87例接受了药师电话干预。在这些患者中,遗忘(25.29%)和医生问题,如预约困难(16.79%),是最常报告的障碍。在排除从ACEI/ARB改用另一种药物的患者后,157例患者纳入逻辑回归模型。其中,131例继续使用ACEI/ARB并纳入线性回归模型。干预组干预后的平均(±标准差)PDC为0.58(±0.26),对照组为0.29(±0.17)。在调整所有其他基线协变量后,干预在多元线性回归模型中是依从性改善的显著预测因素(β=0.3182,95%置信区间=0.19-0.38,P<0.001)。其他协变量与依从性改善无显著关联。在预测药物停药的逻辑回归模型(停药:26例[是]/131例[否])中,接受干预的患者更有可能继续使用ACEI/ARB(比值比=3.56,95%置信区间=1.06-11.86),而合并症指数较高的患者继续使用的可能性较小(比值比=0.72,95%置信区间=0.53-0.99)。
药师简短电话干预使一组合并高血压和糖尿病的非依从性患者在干预后的6个月内PDC显著改善,停药率降低。干预组和对照组的总体PDC率仍低于推荐的80%。将依从性提高到具有临床意义的值可能需要的不仅仅是药师简短的电话。将动机性访谈技术与随访电话相结合以解决依从性障碍,可能对形成可持续的行为改变和提高药物依从性更有影响力。